---
title: "PAVmed Inc. (PAVM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PAVM.US.md"
symbol: "PAVM.US"
name: "PAVmed Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T02:04:11.397Z"
locales:
  - [en](https://longbridge.com/en/quote/PAVM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PAVM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PAVM.US.md)
---

# PAVmed Inc. (PAVM.US)

## Company Overview

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.pavmed.com](https://www.pavmed.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: E (0.83)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 181 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -95.74% |  |
| Net Profit YoY | -139.28% |  |
| P/B Ratio | 0.17 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6142087.44 |  |
| Revenue | 85000.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -104.46% | E |
| Profit Margin | -21914.12% | E |
| Gross Margin | -340.91% | E |
| Revenue YoY | -95.74% | E |
| Net Profit YoY | -139.28% | E |
| Total Assets YoY | -14.02% | E |
| Net Assets YoY | -38.95% | E |
| Cash Flow Margin | 21.95% | D |
| OCF YoY | -95.74% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 44.98% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - PAVmed Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-95.74%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-139.28%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.17",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6142087.44",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "85000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-104.46%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-21914.12%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-340.91%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-95.74%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-139.28%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-14.02%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-38.95%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "21.95%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-95.74%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.98%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.22 | 66/183 | 0.15 | 0.14 | 0.12 |
| PB | 0.18 | 3/183 | 1.09 | 0.86 | 0.58 |
| PS (TTM) | 74.47 | 133/183 | 318.55 | 87.90 | 6.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.40 |
| Highest Target | 65.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PAVM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PAVM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PAVM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PAVM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**